Anti‐prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15‐year longitudinal study

Summary.  Objective: To evaluate the role of anti‐prothrombin (anti‐PT) antibodies in predicting thrombosis in patients with systemic lupus erythematosus (SLE). Methods: An inception cohort of 101 SLE patients (12 males, 89 females; mean age 30 ± 8 years), was considered. Clinical and laboratory evaluations were regularly performed during a 15‐year follow‐up (median 108 months) with a special focus on thromboembolic events. Serum samples were collected at time of diagnosis and at least once a year thereafter. IgG and IgM anti‐PT, anti‐cardiolipin (aCL) and anti‐β2glycoprotein I (β2GPI) antibodies were measured by enzyme‐linked immunosorbent assay (ELISA); lupus anticoagulant (LAC) was assayed by the dilute Russell’s viper venom time and activated partial thromboplastin time tests. The analytical specificity of anti‐PT ELISA was investigated. The timing of thrombosis occurrence was calculated using the Kaplan–Meier method. Results: In the 15‐year follow‐up, thrombosis occurred in 14 out of the 101 patients: venous thrombosis in nine cases and arterial thrombosis in five. IgG and/or IgM anti‐PT, anti‐β2GPI and aCL antibodies, and LAC activity were detected in ten, nine, seven, and nine cases, with sensitivity for thrombosis of 71.4%, 64.3%, 50% and 64.3%, respectively. Thrombosis‐free survival was 90% at 5 years and 85.8% at 10 and 15 years, respectively. Thrombosis was predicted by anti‐PT (P = 0.001), anti‐β2GPI antibodies (P = 0.002) and LAC activity (P = 0.001). Moreover, the risk of thrombosis progressively increased with the number of positive antiphospholipid antibody tests. The presence of four positive antibody tests was associated with a risk of thrombosis thirtyfold higher than in their absence. Conclusions: This longitudinal study shows that IgG anti‐PT antibodies are predictors of thrombosis in SLE patients.

[1]  S. Ito,et al.  Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays , 2006, Modern rheumatology.

[2]  M. Martinuzzo,et al.  A prospective study of antibodies to β2‐glycoprotein I and prothrombin, and risk of thrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[3]  T. Barbui,et al.  Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C , 2005, British journal of haematology.

[4]  N. Bizzaro,et al.  Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. , 2005, Archives of pathology & laboratory medicine.

[5]  T. Nakano,et al.  High prevalence of anti‐prothrombin antibody in patients with deep vein thrombosis , 2004, American journal of hematology.

[6]  M. Galli.  Antiphospholipid Syndrome: Association Between Laboratory Tests and Clinical Practice , 2003, Pathophysiology of Haemostasis and Thrombosis.

[7]  T. Barbui,et al.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.

[8]  Y. Shoenfeld,et al.  Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model , 2003, Lupus.

[9]  Y. Shoenfeld,et al.  Antiprothrombin Antibodies are Associated with Pregnancy Loss in Patients with the Antiphospholipid Syndrome , 2003, American journal of reproductive immunology.

[10]  T. Koike,et al.  Clinical relevance of antiprothrombin antibodies. , 2002, Autoimmunity reviews.

[11]  M. Boffa,et al.  Lupus Anticoagulants: Detection, Standardization, and Heterogeneity , 2002 .

[12]  Y. Kanakura,et al.  Anti‐prothrombin antibodies combined with lupus anti‐coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus , 2001, British journal of haematology.

[13]  J. Amiral,et al.  A Cross Sectional Study of Antiphospholipid-protein Antibodies in Patients with Venous Thromboembolism , 2001, Thrombosis and Haemostasis.

[14]  P. D. de Groot,et al.  Complexes of anti‐prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces , 2001, British journal of haematology.

[15]  Y. Kanakura,et al.  Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. , 2001, Clinical chemistry.

[16]  D. Isenberg,et al.  Anti‐prothrombin antibodies: assay conditions and clinical associations in the anti‐phospholipid syndrome , 2001, British journal of haematology.

[17]  A. Tsutsumi,et al.  Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. , 2000, Arthritis and rheumatism.

[18]  M. Zeher,et al.  Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. , 2000, The Journal of rheumatology.

[19]  G. Espinosa,et al.  Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. , 2000, Haematologica.

[20]  L. Carreras,et al.  Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with history of thrombosis. , 1999, The Journal of laboratory and clinical medicine.

[21]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[22]  T. Exner,et al.  A Monoclonal Antibody against Prothrombin Fragment 1 Behaves Like a Lupus Anticoagulant , 1999, Thrombosis and Haemostasis.

[23]  J. Virtamo,et al.  High Antibody Levels to Prothrombin Imply a Risk of Deep Venous Thrombosis and Pulmonary Embolism in Middle-aged Men , 1997, Thrombosis and Haemostasis.

[24]  O. Vaarala,et al.  Antibodies to Prothrombin Imply a Risk of Myocardial Infarction in Middle-Aged Men , 1996, Thrombosis and Haemostasis.

[25]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[26]  J. Mcintyre,et al.  Effect of storage conditions on the ELISA activity of antiphospholipid antibodies. , 1994, Thrombosis and haemostasis.

[27]  G. Hughes,et al.  STANDARDISING THE ANTI-CARDIOLIPIN ANTIBODY TEST , 1987, The Lancet.

[28]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[29]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.

[30]  L. Ruilope,et al.  INDOMETHACIN AND β-BLOCKERS IN HYPERTENSION , 1978, The Lancet.